These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 25722448)

  • 21. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Basaco Bernabeu T; Mansi R; Del Pozzo L; Zanger S; Gaonkar RH; McDougall L; De Rose F; Jaafar-Thiel L; Herz M; Eiber M; Ulaner GA; Weber WA; Fani M
    J Nucl Med; 2024 Sep; 65(9):1427-1434. PubMed ID: 39025646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
    Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
    Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
    Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
    J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
    Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
    Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Study of CTT1057, an
    Behr SC; Aggarwal R; VanBrocklin HF; Flavell RR; Gao K; Small EJ; Blecha J; Jivan S; Hope TA; Simko JP; Kurhanewicz J; Noworolski SM; Korn NJ; De Los Santos R; Cooperberg MR; Carroll PR; Nguyen HG; Greene KL; Langton-Webster B; Berkman CE; Seo Y
    J Nucl Med; 2019 Jul; 60(7):910-916. PubMed ID: 30464040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent
    Wang Z; Jacobson O; Tian R; Mease RC; Kiesewetter DO; Niu G; Pomper MG; Chen X
    Bioconjug Chem; 2018 Jul; 29(7):2309-2315. PubMed ID: 29865797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Linker Modification on Tumor-to-Kidney Contrast of
    Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
    [No Abstract]   [Full Text] [Related]  

  • 32. Preclinical dosimetric studies of
    Meléndez-Alafort L; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Turato S; Fracasso G; Bolzati C; Rosato A; De Nardo L
    Med Phys; 2021 Jul; 48(7):4064-4074. PubMed ID: 33966284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
    Ling X; Latoche JD; Choy CJ; Kurland BF; Laymon CM; Wu Y; Salamacha N; Shen D; Geruntho JJ; Rigatti LH; Windish HP; Langton-Webster B; Berkman CE; Anderson CJ
    Mol Imaging Biol; 2020 Apr; 22(2):274-284. PubMed ID: 31321650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
    Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation Dosimetry of
    Urbán S; Meyer C; Dahlbom M; Farkas I; Sipka G; Besenyi Z; Czernin J; Calais J; Pávics L
    J Nucl Med; 2021 Aug; 62(8):1075-1081. PubMed ID: 33277398
    [No Abstract]   [Full Text] [Related]  

  • 37. Development and dosimetry of
    Dos Santos JC; Schäfer M; Bauder-Wüst U; Lehnert W; Leotta K; Morgenstern A; Kopka K; Haberkorn U; Mier W; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1081-1091. PubMed ID: 30603987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiolabeling of PSMA-617 with
    Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
    Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer.
    Mease RC; Dusich CL; Foss CA; Ravert HT; Dannals RF; Seidel J; Prideaux A; Fox JJ; Sgouros G; Kozikowski AP; Pomper MG
    Clin Cancer Res; 2008 May; 14(10):3036-43. PubMed ID: 18483369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen.
    Lewis MR; Schaedler AW; Ho KV; Golzy M; Mathur A; Pun M; Gallazzi F; Watkinson LD; Carmack TL; Sikligar K; Anderson CJ; Smith CJ
    Nucl Med Biol; 2024; 136-137():108938. PubMed ID: 39032262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.